Post-trial follow-up | Updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
31 Oct, 2022 | 13:36h | UTC
Commentary on Twitter
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab https://t.co/hw7Tp9yjdu pic.twitter.com/CqMu2cMqRc
— Blood Journal (@BloodJournal) August 31, 2022